10 Best Biotech Stocks with Highest Upside Potential
On April 16, reports from J.P. Morgan's biopharma and medtech venture and licensing studies indicated that the capital markets began the year 2026 with selective strength.
Ocular Therapeutix Inc (OCUL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 19,686,282 | $166,742,809 | +144% | 2.72% |
| 2. | VenBio Select Advisor Kurt Von Emster | 12,315,000 | $104,308,050 | +15% | 1.03% |
| 3. | Point72 Asset Management Steve Cohen | 5,534,985 | $46,881,323 | +445% | 0.06% |
| 4. | Logos Capital Arsani William | 3,850,000 | $32,609,500 | +10% | 1.63% |
| 5. | Octagon Capital Advisors Ting Jia | 3,166,600 | $26,821,102 | +21% | 2.97% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.66 | 60,229 | $461,354.14 | 246,933 | 2026-02-20 | Filing | |
| $6.96 | 10,000 | $69,600.00 | 172,704 | 2025-05-08 | Filing | |
| $7.52 | 930,851 | $6,999,999.52 | 8,591,401 | 2024-02-26 | Filing | |
| $3.25 | 1,538,461 | $4,999,998.25 | 7,660,550 | 2023-12-14 | Filing | |
| $3.81 | 6,500 | $24,765.00 | 6,500 | 2023-08-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.20 | 21,156 | $173,479.20 | 2,597,170 | 2026-05-26 | Filing | |
| $8.20 | 2,967 | $24,329.40 | 266,141 | 2026-05-26 | Filing | |
| $8.20 | 3,018 | $24,747.60 | 320,350 | 2026-05-26 | Filing | |
| $8.20 | 1,858 | $15,235.60 | 328,795 | 2026-05-26 | Filing | |
| $8.28 | 20,056 | $166,063.68 | 3,013,022 | 2026-02-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 32,653,764 | $276,577,378 | 0.01% | |
| 2. | 16,132,931 | $136,645,927 | 0% | |
| 3. | 11,879,825 | $100,622,118 | 70.84% | |
| 4. | 10,346,926 | $87,638,463 | 3.27% | |
| 5. | 8,719,039 | $73,850,260 | 0% |
News See All
Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLI
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best low priced biotech stocks to invest in. Ocular Therapeutix Inc.
8 Best Low Priced Biotech Stocks to Invest In
On April 16, Fundstrat’s Tom Lee appeared on CNBC's 'Closing Bell' to talk about what to expect from equity markets going forward.
10 Stocks With Easy 9-30% Upside
Sandisk climbed to a fresh all-time high on Thursday, as investors gobbled up shares following Bernstein SocGen Group’s 25-percent price target upgrade for its stock while positioning portfolios ahead...
7 Best Small-Cap Healthcare Stocks to Buy According to Hedge Funds
In this article, we will look at the best small-cap healthcare stocks to buy according to hedge funds.
Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory
We came across a bullish thesis on Ocular Therapeutix, Inc. on r/Valueinvesting by Senior-Preference678. In this article, we will summarize the bulls’ thesis on OCUL.
Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory
We came across a bullish thesis on Ocular Therapeutix, Inc. on TipRanks’ YouTube channel. In this article, we will summarize the bulls’ thesis on OCUL.
BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the low priced stocks to buy with high upside potential.
12 Low Priced Stocks to Buy with High Upside Potential
On December 27, Michael Farr of Farr Miller & Washington appeared on CNBC's 'Closing Bell Overtime' to talk about his market predictions for 2026.
H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix Inc.
Hedge Fund Resource Center